Amgen (NASDAQ:AMGN) is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares.

Big drug companies such as Amgen, AbbVie (NYSE:ABBV), and Johnson & Johnson (NYSE:JNJ) offer investors predictable dividend-friendly revenue regardless of the economy's whims and whispers. But investors are correct to wonder whether Amgen's dividend can be sustained in light of billions in at-risk revenue tied to the future patent expiration of top-selling drugs.

In the following slideshow you'll see whether I think Amgen's dividend is safe and gain insight into how Amgen's dividend payout matches up with industry peers AbbVie and Johnson & Johnson.